A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)

[1]  J. Clark,et al.  Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion , 2013, Oncogene.

[2]  V. Roy,et al.  Immunomodulatory drugs in multiple myeloma , 2013, Expert review of hematology.

[3]  D. Hose,et al.  High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. , 2013, Blood.

[4]  H. Avet-Loiseau,et al.  Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+multiple Myeloma Cells , 2012 .

[5]  S. Karasawa,et al.  Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide , 2012, Leukemia.

[6]  J. Lancet,et al.  Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. , 2012, Blood.

[7]  A. Jankowska,et al.  Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide , 2012, Journal of Hematology & Oncology.

[8]  P. Fenaux,et al.  Immunomodulating drugs in myelodysplastic syndromes. , 2011, Hematology. American Society of Hematology. Education Program.

[9]  P. L. Bergsagel,et al.  Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. , 2011, Blood.

[10]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[11]  Toshihiko Ogura,et al.  Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.

[12]  Pablo Tamayo,et al.  An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome , 2008, PLoS medicine.

[13]  J. Reeves,et al.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. , 2008, Blood.

[14]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[15]  P. Venugopal,et al.  Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. , 2001, Blood.